Opus Genetics appoints Robert Gagnon as CFO effective September 2, 2025

Opus Genetics, Inc.

Annual base salary of $465,000, eligible for annual bonus up to 45% of base.
Stock option for 250,000 shares and restricted stock award for 200,000 shares, both vesting over four years.
Gagnon previously CFO of Remix Therapeutics and Verastem Oncology; has raised over $2B in capital.
Appointment is part of Opus's advancement of clinical pipeline for inherited retinal diseases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.